Renaissance Capital logo

Atara Biotherapeutics Priced, Nasdaq: ATRA

Early-stage biotech targeting muscle loss in patients with end-stage renal disease.

Industry: Health Care

First Day Return: -3.2%

Industry: Health Care

Early-stage biotech targeting muscle loss in patients with end-stage renal disease.
more less

Atara Biotherapeutics (ATRA) Performance